John C. Victor

John C. Victor

Auto-generated profile, based on publicly available information

John C. Victor

PATH, Seattle, Washington

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in The Lancet
Verified
Journal Article
Closed access
GAGeorge E Armah
George E Armah
SSSamba O Sow
Samba O Sow
RBRobert F Breiman
Robert F Breiman
MDMichael J Dallas
Michael J Dallas
MTMilagritos D Tapia
Milagritos D Tapia
KNKathleen M Neuzil
Kathleen M Neuzil

1 August 2010 in The Lancet
Verified
Journal Article
Closed access
KZK Zaman
K Zaman
DADang Duc Anh
Dang Duc Anh
JVJohn C Victor
John C Victor
SSSunheang Shin
Sunheang Shin
YUYunus
Yunus
MCMax Ciarlet
Max Ciarlet

1 September 1998 in Journal of Medical Entomology
Verified
Journal Article
Closed access
PDF file
DDDavid T. Dennis
David T. Dennis
TNTrudi S. Nekomoto
Trudi S. Nekomoto
JVJohn C. Victor
John C. Victor
WPWilliam S. Paul
William S. Paul
JPJoseph Piesman
Joseph Piesman
Lyme disease, caused by infection with Borrelia burgdorferi, is the most frequently reported arthropod-borne disease in the United States. To develop a national map of the distribution of the vectors of B. burgdorferi to humans (Ixodes scapularis Say and Ixodes pacificus Cooley & Kohls ticks), we sent questionnaires to acarologists, health officials, and Lyme disease researchers; surveyed the 1966–1996 MEDLINE data base; and reviewed 1907–1995 National Tick Collection data. Tick collection methods cited included flagging and dragging, deer surveys, small- and medium-sized mammal surveys, CO2 baiting, and receipt of tick submissions. A total of 1,058 unique, county-specific I. scapularis and I. pacificus records was obtained. Tick populations were classified as“reported”(1 life stage identified). Established populations of I. scapularis were identified in 396 counties in 32 states in the eastern and central United States, whereas established populations of, I. pacificus were found in 90 counties in 5 western states. Counties with established populations were most concentrated in the northeastern, upper northcentral, and west-coastal states but were also clustered in southeastern and Gulf-coastal states. A less concentrated distribution was found in the south-central states. Reports were notably missing from all but a few counties in Ohio, West Virginia, western Virginia and North Carolina, Kentucky, and Tennessee. They were absent in the Great Plains and Rocky Mountain regions and from large areas of western states east of the Cascade and Sierra Nevada Cordilleras. These data are useful for identifying areas of Lyme disease risk, for targeting Lyme disease prevention strategies, and for monitoring trends in spatial distribution of Lyme disease vector ticks.

14 December 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SOSuzanne E. Ohmit
Suzanne E. Ohmit
JVJohn C. Victor
John C. Victor
JRJudy R. Rotthoff
Judy R. Rotthoff
ETEsther R. Teich
Esther R. Teich
RTRachel K. Truscon
Rachel K. Truscon
AMArnold S. Monto
Arnold S. Monto
The efficacy of influenza vaccines may decline during years when the circulating viruses have antigenically drifted from those included in the vaccine. We carried out a randomized, double-blind, placebo-controlled trial of inactivated and live attenuated influenza vaccines in healthy adults during the 2004–2005 influenza season and estimated both absolute and relative efficacies. A total of 1247 persons were vaccinated between October and December 2004. Influenza activity in Michigan began in January 2005 with the circulation of an antigenically drifted type A (H3N2) virus, the A/California/07/2004-like strain, and of type B viruses from two lineages. The absolute efficacy of the inactivated vaccine against both types of virus was 77% (95% confidence interval [CI], 37 to 92) as measured by isolating the virus in cell culture, 75% (95% CI, 42 to 90) as measured by either isolating the virus in cell culture or identifying it through real-time polymerase chain reaction, and 67% (95% CI, 16 to 87) as measured by either isolating the virus or observing a rise in the serum antibody titer. The absolute efficacies of the live attenuated vaccine were 57% (95% CI, −3 to 82), 48% (95% CI, −7 to 74), and 30% (95% CI, −57 to 67), respectively. The difference in efficacy between the two vaccines appeared to be related mainly to reduced protection of the live attenuated vaccine against type B viruses. In the 2004–2005 season, in which most circulating viruses were dissimilar to those included in the vaccine, the inactivated vaccine was efficacious in preventing laboratory-confirmed symptomatic illnesses from influenza in healthy adults. The live attenuated vaccine also prevented influenza illnesses but was less efficacious. (ClinicalTrials.gov number, NCT00133523.)

24 September 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AMArnold S Monto
Arnold S Monto
SOSuzanne E. Ohmit
Suzanne E. Ohmit
JPJoshua G. Petrie
Joshua G. Petrie
EJEmileigh Johnson
Emileigh Johnson
RTRachel Truscon
Rachel Truscon
JVJohn C. Victor
John C. Victor
The efficacy of influenza vaccines may vary from year to year, depending on a variety of factors, and may differ for inactivated and live attenuated vaccines.

25 October 2007 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JVJohn C. Victor
John C. Victor
AMArnold S. Monto
Arnold S. Monto
TSTatiyana Y. Surdina
Tatiyana Y. Surdina
SSSaida Z. Suleimenova
Saida Z. Suleimenova
GVGilberto Vaughan
Gilberto Vaughan
BBBeth P. Bell
Beth P. Bell
Hepatitis A vaccine administered to persons after exposure to the hepatitis A virus has not been compared directly with immune globulin, which is known to be highly effective in preventing hepatitis A when given within 2 weeks after exposure to the virus.